US5968983A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method and formulation for treating vascular disease
Assignee: Palmetto Pharmaceuticals LLC
•
Filing: 1997-04-10
•
Granted: 1999-10-19
•
Expires: 2017-04-10
Abstract
Abstract A therapeutic mixture comprised of L-arginine and inhibitors of Hmg--CoA-Reductase is disclosed for the treatment of diseases related to endothelial dysfunction, wherein the endothelial dysfunction is relieved by stimulating the constitutive form of nitric oxide synthase (cNOS) to produce native nitric oxide (NO).
Inventors
- 👤 Wayne H. Kaesemeyer
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 08:13
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/44; A61K31/185; A61K31/19; A61K31/195; A61K31/197; A61K31/198; A61K31/21; A61K31/215; A61K31/22; A61K31/335; A61K31/365; A61K31/40; A61K31/41; A61K31/495; A61K31/50; A61K31/66; A61K31/675; A61P; A61P43/00; A61P9/00; A61P9/10
Claims Analysis
Total Claims: 22
Claim 1
Independent Claim
82 words
A method of treating a disease condition in a subject by vasodilation or vasorelaxation comprising: selecting a subject; administering a mixture of L-arginine and an inhibitor of Hmg--CoA reductase wherein said inhibitor of Hmg--CoA reductase is selected from the group consisting of: lovastatin; pravastatin; simvastatin; fluvastatin; dalvastatin; compactin; HR-780; BMY 22,089; BMY 22,566; SQ 33,600; GR 95,030; or CI 981; obtaining periodic indicators of vasorelaxations for the subject; and continuing administration of the mixture until a desirable state of vasorelaxation is obtained.
Claim 2
Independent Claim
82 words
A method of treating a disease condition in a subject by vasodilation or vasorelaxation comprising: selecting a subject; administering a mixture of L-arginine and an inhibitor of Hmg--CoA reductase wherein said inhibitor of Hmg--CoA reductase is selected from the group consisting of: lovastatin; pravastatin; simvastatin; fluvastatin; dalvastatin; compactin; HR-780; BMY 22,089; BMY 22,566; SQ 33,600; GR 95,030; or CI 981; obtaining periodic indicators of vasorelaxations for the subject; and continuing administration of the mixture until a desirable state of vasorelaxation is obtained.
Claim 3
Dependent Claim
24 words
The method of claim 1, wherein the formulation is administered intravenously, buccal, intracoronary, intramuscularly, topically, intranasally, rectally, sublingually, orally, subcutaneously, by patch, or inhalation.
Claim 4
Dependent Claim
23 words
The method of claim 1, wherein said disease is hypertension, hypertensive heart disease, coronary heart disease, cardiovascular disease, cerebrovascular disease, and renovascular disease.
Claim 5
Dependent Claim
14 words
The method of claim 3, wherein said coronary heart disease is restenosis post angioplasty.
Claim 6
Dependent Claim
17 words
The method of claim 1, wherein L-arginine and said inhibitor of Hmg--CoA reductase are mixed in vivo.
Claim 7
Dependent Claim
19 words
The method of claim 5, wherein L-arginine and said inhibitor of Hmg--CoA reductase are administered at a therapeutic concentration.
Claim 8
Dependent Claim
19 words
The method of claim 6, wherein the therapeutic concentration of L-arginine is from 7.5% to about 30% w/v (g/ml).
Claim 9
Dependent Claim
19 words
The method of claim 6, wherein the therapeutic concentration of L-arginine is from 10% to about 15% w/v (g/ml).
Claim 10
Dependent Claim
15 words
The method of claim 6, wherein the therapeutic concentration of L-arginine is 10% w/v (g/ml).
Claim 11
Dependent Claim
17 words
The method of claim 6, wherein the pH is maintained within the range of 6 to 8.0.
Claim 12
Dependent Claim
17 words
The method of claim 6, wherein the pH is maintained within the range of 7 to 7.4.
Claim 13
Dependent Claim
13 words
The method of claim 1, wherein said inhibitor of Hmg--CoA reductase is pravastatin.
Claim 14
Dependent Claim
52 words
A therapeutic mixture comprised of an inhibitor of Hmg--CoA reductase and a substrate of NOS, said substrate of NOS being a biological equivalent of arginine, said inhibitor being selected from the group consisting of: lovastatin; pravastatin; simvastatin; fluvastatin; dalvastatin; compactin; HR-780; BMY 22,089; BMY 22,566; SQ 33,600; GR 95,030; or CI 981.
Claim 15
Dependent Claim
52 words
A therapeutic mixture comprised of an inhibitor of Hmg--CoA reductase and a substrate of NOS, said substrate of NOS being a biological equivalent of arginine, said inhibitor being selected from the group consisting of: lovastatin; pravastatin; simvastatin; fluvastatin; dalvastatin; compactin; HR-780; BMY 22,089; BMY 22,566; SQ 33,600; GR 95,030; or CI 981.
Claim 16
Dependent Claim
17 words
The therapeutic mixture of claim 13, wherein said inhibitor of Hmg--CoA reductase is an agonist of NOS.
Claim 17
Dependent Claim
14 words
The therapeutic mixture of claim 13, wherein said inhibitor of Hmg--CoA reductase is pravastatin.
Claim 18
Dependent Claim
22 words
The therapeutic mixture of claim 13, wherein said inhibitor of Hmg--CoA reductase is pravastatin and said biological equivalent of arginine is L-arginine.
Claim 19
Independent Claim
81 words
A method of stimulating nitric oxide synthase to produce nitric oxide, said method comprising: administering L-arginine and an agonist of nitric oxide synthase to a subject have a nitric oxide synthase receptor site, said agonist being different than L-arginine and being selected from the group consisting of: lovastatin; pravastatin; simvastatin; fluvastatin; dalvastatin; compactin; HR-780; BMY 22,089; BMY 22,566; SQ 33,600; GR 95,030; or CI 981 stimulating said nitric oxide synthase to a desirable level with said agonist of nitric oxide synthase.
Claim 20
Independent Claim
81 words
A method of stimulating nitric oxide synthase to produce nitric oxide, said method comprising: administering L-arginine and an agonist of nitric oxide synthase to a subject have a nitric oxide synthase receptor site, said agonist being different than L-arginine and being selected from the group consisting of: lovastatin; pravastatin; simvastatin; fluvastatin; dalvastatin; compactin; HR-780; BMY 22,089; BMY 22,566; SQ 33,600; GR 95,030; or CI 981 stimulating said nitric oxide synthase to a desirable level with said agonist of nitric oxide synthase.
Claim 21
Dependent Claim
14 words
The method of claim 17, wherein said L-arginine is in excess to said agonist.
Claim 22
Dependent Claim
26 words
The method of claim 17, wherein therapeutically effective amounts of L-arginine is combined with therapeutically effective amounts of said agonist prior to administering to the patient.
References Cited (Backward Citations)
US5366738A
Cited
US4686211A
Cited
US5316765A
Cited
US5059712A
Cited
US5158883A
Cited
US5196195A
Cited
US5132453A
Cited
US5273875A
Cited
US5428070A
Cited
US5543430A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2002-10-18 | 2003-04-19 | 2003-10-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2006-10-18 | 2007-04-19 | 2007-10-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2010-10-18 | 2011-04-19 | 2011-10-19 | $7700.00 | Window Closed / Lapsed |